Why the study?
Major adverse cardiovascular events remain the major cause of mortality and morbidity in patients with STEMI.
What is the incidence of major adverse cardiovascular events (MACE) in patients aged 45 and older following STEMI irrespective of the treatment modality?
What is the incidence of major adverse cardiovascular events (MACE) in patients aged 45 and older following STEMI irrespective of the treatment modality?
MACE remains a highly prevalent adverse outcome among STEMI patients, with an incidence ranging from 4.2% to 51%, highlighting the ongoing need for optimized management strategies.
Long-term secondary prevention remains essential after STEMI regardless of acute therapy; leaves open which strategies best reduce residual MACE.
Major adverse cardiovascular events (MACE) remain the major cause of mortality and morbidity in patients with STEMI (ST-elevation myocardial infarction). The current literature is aimed to analyze the occurrence of MACE following STEMI irrespective of treatment provided, and follow up after the first diagnosis of STEMI. A PubMed search for Studies of STEMI identified 24,244 articles. After applying our inclusion/exclusion criteria, we found out 75 articles of relevance wherein MACE and its components were considered to be the primary endpoint. These 75 articles included eight Cohort Studies, 13 clinical trials including five randomized controlled trials (RCT), one case-control Study, one cross-sectional study, one review article, and 51 other observational studies. Our analysis shows that MACE remains one of the strongest adverse outcomes among STEMI patients. The current literature review found out the incidence of MACE was 4.2 % to 51% irrespective of the mode of treatment, and follow-ups lasting up to 10 years from the time of STEMI diagnosis.
No takes yet. Share an insight, caveat, or question.
Poudel et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: